Dyne Therapeutics plans to announce topline clinical results from the Phase 1/2 DELIVER trial of zeleciment rostudirsen on December 8, 2025. The company will host a webcast at 8:00 a.m. ET and issue a press release prior to the event. The webcast will be available on Dyne’s website with a replay accessible for 90 days. Dyne Therapeutics focuses on developing therapeutics for neuromuscular diseases like myotonic dystrophy type 1 and Duchenne muscular dystrophy. Investors can contact Mia Tobias at [email protected], while media inquiries can be directed to Stacy Nartker at [email protected].

Read more at GlobeNewswire: Dyne Therapeutics to Host Investor Conference Call and